US4444887A
(en)
|
1979-12-10 |
1984-04-24 |
Sloan-Kettering Institute |
Process for making human antibody producing B-lymphocytes
|
US4716111A
(en)
|
1982-08-11 |
1987-12-29 |
Trustees Of Boston University |
Process for producing human antibodies
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
US4970300A
(en)
|
1985-02-01 |
1990-11-13 |
New York University |
Modified factor VIII
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
GB8720833D0
(en)
|
1987-09-04 |
1987-10-14 |
Celltech Ltd |
Recombinant dna product
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
GB8907617D0
(en)
|
1989-04-05 |
1989-05-17 |
Celltech Ltd |
Drug delivery system
|
US5413923A
(en)
|
1989-07-25 |
1995-05-09 |
Cell Genesys, Inc. |
Homologous recombination for universal donor cells and chimeric mammalian hosts
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
SG48759A1
(en)
|
1990-01-12 |
2002-07-23 |
Abgenix Inc |
Generation of xenogenic antibodies
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
EP0546073B1
(en)
|
1990-08-29 |
1997-09-10 |
GenPharm International, Inc. |
production and use of transgenic non-human animals capable of producing heterologous antibodies
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
DE69233482T2
(en)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Method for reducing the immunogenicity of antibody variable domains
|
IE922437A1
(en)
|
1991-07-25 |
1993-01-27 |
Idec Pharma Corp |
Recombinant antibodies for human therapy
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
DE69233782D1
(en)
|
1991-12-02 |
2010-05-20 |
Medical Res Council |
Preparation of Autoantibodies on Phage Surfaces Starting from Antibody Segment Libraries
|
SG42861A1
(en)
|
1992-04-10 |
1997-10-17 |
Sprintpak Pty Ltd |
Postage stamps
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
AU6029594A
(en)
|
1993-01-15 |
1994-08-15 |
Enzon, Inc. |
Factor viii - polymeric conjugates
|
EP1978033A3
(en)
|
1995-04-27 |
2008-12-24 |
Amgen Fremont Inc. |
Human antibodies derived from immunized xenomice
|
CA2219486A1
(en)
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
WO1997003193A1
(en)
|
1995-07-11 |
1997-01-30 |
Chiron Corporation |
Novel factor viii:c polypeptide analogs with altered metal-binding properties
|
SE9503380D0
(en)
|
1995-09-29 |
1995-09-29 |
Pharmacia Ab |
Protein derivatives
|
JP3987114B2
(en)
|
1996-04-24 |
2007-10-03 |
ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン |
Inactivation resistance factor (8)
|
US20040092442A1
(en)
|
1996-04-24 |
2004-05-13 |
University Of Michigan |
Inactivation resistant factor VIII
|
US5916771A
(en)
|
1996-10-11 |
1999-06-29 |
Abgenix, Inc. |
Production of a multimeric protein by cell fusion method
|
ES2301183T3
(en)
|
1996-12-03 |
2008-06-16 |
Amgen Fremont Inc. |
COMPLETELY HUMAN ANTIBODY THAT JOINS THE EGFR RECEIVER.
|
GB9625640D0
(en)
|
1996-12-10 |
1997-01-29 |
Celltech Therapeutics Ltd |
Biological products
|
RU2224766C2
(en)
|
1997-04-14 |
2004-02-27 |
Микромет Аг |
Method for preparing receptors for human antigens and their application
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
PT1079805E
(en)
|
1998-04-27 |
2005-03-31 |
Opperbas Holding Bv |
PHARMACEUTICAL COMPOSITION UNDERSTANDING FACTOR VIII AND NEUTRAL LIPOSOMES
|
ATE384792T1
(en)
|
1998-11-18 |
2008-02-15 |
Genentech Inc |
ANTIBODY VARIANTS WITH HIGHER BINDING AFFINITIES COMPARED TO PARENTAL ANTIBODIES
|
EP1351986A2
(en)
|
2001-01-12 |
2003-10-15 |
The American National Red Cross |
Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
|
JP4361786B2
(en)
|
2001-06-14 |
2009-11-11 |
ザ スクリプス リサーチ インスティチュート |
Stabilized proteins with engineered disulfide bonds
|
ES2516041T3
(en)
|
2001-10-10 |
2014-10-30 |
Ratiopharm Gmbh |
Remodeling and glycoconjugation of human growth hormone (hGH)
|
AU2003227687B2
(en)
|
2002-04-29 |
2009-10-15 |
Stichting Sanquin Bloedvoorziening |
Antagonists of factor VIII interaction with low-density lipoprotein receptor-related protein
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7365168B2
(en)
|
2002-10-15 |
2008-04-29 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7217798B2
(en)
|
2003-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of Fc-fusion protein serum half-lives by mutagenesis
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7041635B2
(en)
|
2003-01-28 |
2006-05-09 |
In2Gen Co., Ltd. |
Factor VIII polypeptide
|
EP1596887B1
(en)
|
2003-02-26 |
2022-03-23 |
Nektar Therapeutics |
Polymer-factor viii moiety conjugates
|
ES2558102T3
(en)
|
2003-05-06 |
2016-02-02 |
Biogen Hemophilia Inc. |
Chimeric coagulation factor proteins for the treatment of a hemostatic disorder
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
GB0412181D0
(en)
|
2004-06-01 |
2004-06-30 |
Celltech R&D Ltd |
Biological products
|
LT3130601T
(en)
|
2004-11-12 |
2020-09-10 |
Bayer Healthcare Llc |
Site-directed modification of fviii
|
PT1835938E
(en)
|
2004-12-27 |
2013-11-06 |
Baxter Int |
Polymer-von willebrand factor-conjugates
|
AU2006233638A1
(en)
|
2005-04-14 |
2006-10-19 |
Csl Behring Gmbh |
Modified coagulation Factor VIII with enhanced stability and its derivates
|
US7645860B2
(en)
|
2006-03-31 |
2010-01-12 |
Baxter Healthcare S.A. |
Factor VIII polymer conjugates
|
US7985839B2
(en)
|
2006-03-31 |
2011-07-26 |
Baxter International Inc. |
Factor VIII polymer conjugates
|
US7982010B2
(en)
|
2006-03-31 |
2011-07-19 |
Baxter International Inc. |
Factor VIII polymer conjugates
|
AU2007245190B2
(en)
|
2006-03-31 |
2011-07-21 |
Takeda Pharmaceutical Company Limited |
Pegylated factor VIII
|
JP5448839B2
(en)
|
2006-12-22 |
2014-03-19 |
ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー |
Modified clotting factor with long half-life in vivo
|
CN101678119B
(en)
|
2006-12-27 |
2014-02-12 |
尼克塔治疗公司 |
Von willebrand factor- and factor VIII-polymer conjugates having releasable linkage
|
EP1988101A1
(en)
|
2007-05-04 |
2008-11-05 |
Novo Nordisk A/S |
Improvement of factor VIII polypeptide titers in cell cultures
|
ES2392569T3
(en)
*
|
2007-06-13 |
2012-12-11 |
Csl Behring Gmbh |
Use of VWF stabilized FVIII preparations for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
|
DE602008005885D1
(en)
|
2007-07-11 |
2011-05-12 |
Novo Nordisk As |
PURIFICATION OF FACTOR VIII USING ONE
|
KR20100095441A
(en)
|
2007-11-09 |
2010-08-30 |
백스터 인터내셔널 인코포레이티드 |
Modified recombinant factor viii and von willebrand factor and methods of use
|
EP2257311B1
(en)
|
2008-02-27 |
2014-04-16 |
Novo Nordisk A/S |
Conjugated factor viii molecules
|
CN102076855A
(en)
|
2008-06-24 |
2011-05-25 |
Csl百灵有限公司 |
Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
|
ES2692172T3
(en)
|
2008-10-17 |
2018-11-30 |
Baxalta GmbH |
Modified blood factors comprising a low degree of water-soluble polymer
|
CN102333788A
(en)
|
2009-02-19 |
2012-01-25 |
诺沃—诺迪斯克有限公司 |
Modification of factor viii
|
US20120093840A1
(en)
|
2009-04-06 |
2012-04-19 |
Novo Nordisk A/S |
Targeted delivery of factor viii proteins to platelets
|
KR101808751B1
(en)
*
|
2009-11-13 |
2017-12-13 |
그리폴스 테라퓨틱스 인코포레이티드 |
VON WILLEBRAND FACTOR (vWF)-CONTAINING PREPARATIONS, AND METHODS, KITS, AND USES RELATED THERETO
|
US9493543B2
(en)
|
2010-02-16 |
2016-11-15 |
Novo Nordisk A/S |
Factor VIII fusion protein
|
WO2011101277A1
(en)
|
2010-02-16 |
2011-08-25 |
Novo Nordisk A/S |
Conjugated proteins
|
WO2011101242A1
(en)
|
2010-02-16 |
2011-08-25 |
Novo Nordisk A/S |
Factor viii molecules with reduced vwf binding
|
US8859731B2
(en)
|
2010-04-21 |
2014-10-14 |
Novo Nordisk A/S |
Selective modification of proteins
|
EP2593130A2
(en)
|
2010-07-15 |
2013-05-22 |
Novo Nordisk A/S |
Stabilized factor viii variants
|
CN102161692B
(en)
*
|
2011-03-08 |
2013-10-02 |
中国人民解放军第三军医大学 |
Improved hemostatic polypeptide and application thereof
|
WO2013083858A1
(en)
|
2012-04-24 |
2013-06-13 |
Novo Nordisk A/S |
Compounds suitable for treatment of haemophilia
|
EP2662083A1
(en)
*
|
2012-05-08 |
2013-11-13 |
CSL Behring GmbH |
Sugar compositions for treating hemophilia a and/or von willebrand disease
|
ES2657291T3
(en)
*
|
2013-04-22 |
2018-03-02 |
Csl Ltd. |
A covalent complex of von Willebrand factor and factor VIII associated by a disulfide bridge
|
WO2014198699A2
(en)
*
|
2013-06-12 |
2014-12-18 |
Novo Nordisk A/S |
Compounds suitable for treatment of haemophilia
|